Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy

被引:42
作者
Dewald, GW [1 ]
Wyatt, WA [1 ]
Silver, RT [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Div Lab Genet, Rochester, MN 55905 USA
关键词
chronic myeloid leukemia; fluorescence in situ hybridization; therapy;
D O I
10.3109/10428199909058475
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
D-FISH uses DNA probes with fluorescence in situ hybridization to detect two fusion signals in cells with a t(9;22)(q34;q11.2) from patients with chronic myeloid leukemia (CML). Using D-FISH, 147 patients with CML were studied and considerable macro genetic Variation was observed among their Ph-chromosomes. Typical D-FISH signal patterns were observed for 81% of patients, but three different atypical patterns were seen in 19% of patients. Atypical patterns among Ph-chromosomes were consistent with loss of the 3' portion of BCR that is usually translocated to chromosome 9, or loss of the 5' segment of ABL that usually remains on chromosome 9, or loss of both the 3' translocated BCR and 5' residual ABL hybridization sites. Atypical patterns were associated with all forms of Ph-chromosomes including t(9;22)(q34;q1,2), complex translocations and masked. The normal range for 500 interphase nuclei for patients with typical patterns is <1%. By comparison, the normal range for patients with either of two atypical patterns was less than or equal to 1.8% and for patients with the other atypical pattern was less than or equal to 23%. Thus, special scoring criteria are needed to detect and quantify nuclei with atypical patterns using D-FISH. The proportion of patients that responded to therapy with interferon alpha-2b or interferon alpha-2b and ara-C for 36 patients with typical patterns was similar to 7 patients with atypical patterns.
引用
收藏
页码:481 / +
页数:13
相关论文
共 7 条
[1]  
BIERNAUX C, 1995, BLOOD, V86, P3118
[2]   The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease [J].
Bose, S ;
Deininger, M ;
Gora-Tybor, J ;
Goldman, JM ;
Melo, JV .
BLOOD, 1998, 92 (09) :3362-3367
[3]   A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia [J].
Buño, I ;
Wyatt, WA ;
Zinsmeister, AR ;
Dietz-Band, J ;
Silver, RT ;
Dewald, GW .
BLOOD, 1998, 92 (07) :2315-2321
[4]   THE APPLICATION OF FLUORESCENT IN-SITU HYBRIDIZATION TO DETECT MBCR/ABL FUSION IN VARIANT PH CHROMOSOMES IN CML AND ALL [J].
DEWALD, GW ;
SCHAD, CR ;
CHRISTENSEN, ER ;
TIEDE, AL ;
ZINSMEISTER, AR ;
SPURBECK, JL ;
THIBODEAU, SN ;
JALAL, SM .
CANCER GENETICS AND CYTOGENETICS, 1993, 71 (01) :7-14
[5]   Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia [J].
Dewald, GW ;
Wyatt, WA ;
Juneau, AL ;
Carlson, RO ;
Zinsmeister, AR ;
Jalal, SM ;
Spurbeck, JL ;
Silver, RT .
BLOOD, 1998, 91 (09) :3357-3365
[6]  
MELO JV, 1993, BLOOD, V81, P158
[7]   Improved sensitivity of BCR-ABL detection: A triple-probe three-color fluorescence in situ hybridization system [J].
Sinclair, PB ;
Green, AR ;
Grace, C ;
Nacheva, EP .
BLOOD, 1997, 90 (04) :1395-1402